N,N-dimethyl-4-(6-([11C]methylthio)imidazo[1,2-a]pyridin-2-yl)aniline | 955376-43-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N,N-dimethyl-4-(6-([11C]methylthio)imidazo[1,2-a]pyridin-2-yl)aniline
• 英文别名: E6Clv6G2RR；N,N-dimethyl-4-(6-(111C)methylsulfanylimidazo[1,2-a]pyridin-2-yl)aniline
• CAS: 955376-43-9
• 化学式: C₁₆H₁₇N₃S
• 分子量: 282.386
• InChiKey: WOYCDVDURLTMAW-KTXUZGJCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Methyl 3-[2-[4-(dimethylamino)phenyl]imidazo[1,2-a]pyridin-6-yl]sulfanylpropanoate 、 [11C]methyl iodide 在 potassium tert-butylate 作用下， 生成 N,N-dimethyl-4-(6-([11C]methylthio)imidazo[1,2-a]pyridin-2-yl)aniline
  参考文献：
  名称：

  WO2007/124345

  摘要：

  公开号：

文献信息

• Radiolabelling Method Using Cycloalkyl Groups
  申请人：Graham Keith

  公开号：US20120189546A1

  公开（公告）日：2012-07-26

  This invention relates to novel cyclo alkyl compounds suitable for labeling by 18 F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

  本发明涉及新型环烷基化合物，适用于18F标记，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒以及这种化合物、组合物或试剂盒在正电子发射断层扫描（PET）诊断成像中的用途。
• BETA-AMYLOID PET IMAGING AGENTS
  申请人：Cai Lisheng

  公开号：US20110008255A1

  公开（公告）日：2011-01-13

  Novel derivatives of imidazopyridinylbenzeneamines and novel derivatives of benzothiazolylbenzeneamines are disclosed that offer improved behavior when used as imaging agents for positron emission tomography of beta-amyloids. Also disclosed is a palladium-catalyzed reaction scheme under microwave conditions for aryl thioethers in general that provides a high ratio of substitution relative to reduction and can be used for the imidazopyridinylbenzeneamine derivatives as well as other compounds of related structure.

  本发明揭示了新型咪唑吡啶基苯胺衍生物和新型苯并噻唑基苯胺衍生物，用作正电子发射断层扫描成像剂时表现出改进的行为。还揭示了一种钯催化反应方案，在微波条件下对芳基硫醚进行反应，相对于还原提供更高的取代比，并可用于咪唑吡啶基苯胺衍生物以及其他相关结构的化合物。
• Synthesis and Evaluation of <i>N</i>-Methyl and <i>S</i>-Methyl ¹¹C-Labeled 6-Methylthio-2-(4′-<i>N</i>,<i>N</i>-dimethylamino)phenylimidazo[1,2-<i>a</i>]pyridines as Radioligands for Imaging β-Amyloid Plaques in Alzheimer’s Disease
  作者：Lisheng Cai、Jeih-San Liow、Sami S. Zoghbi、Jessica Cuevas、Cesar Baetas、Jinsoo Hong、H. Umesha Shetty、Nicholas M. Seneca、Amira K. Brown、Robert Gladding、Sebastian S. Temme、Mary M. Herman、Robert B. Innis、Victor W. Pike

  DOI：10.1021/jm700970s

  日期：2008.1.1

  6-Thiolato-substituted 2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines (RS-IMPYs; 1-4) were synthesized as candidates for labeling with carbon-11 (t(1/2) = 20.4 min) and imaging of A(beta) plaques in living human brain using positron emission tomography (PET). K-i values for binding of these ligands to Alzheimer's disease brain homogenates were measured in vitro,against tritium-labeled 6 (Pittsburgh compound B). MeS-IMPY (3, K-i = 7.93 nM) was labeled with carbon-11 at its S- or N-methyl position to give [C-11]7 or [C-11]8, respectively. After injection into rats, [C-11]7 or [C-11]8 gave moderately high brain uptakes of radioactivity followed by rapid washout to low levels. The ratio of radioactivity at maximal uptake to that at 60 min reached 18.7 for [C-11]7. [C-11]7 behaved similarly in mouse and monkey. [C-11]7 also bound selectively to A(beta) plaques in post mortem human Alzheimer's disease brain. Although rapidly metabolized in rat by N-demethylation, [C-11]7 was stable in rat brain homogenates. The ex vivo brain radiometabolites observed in rats have a peripheral origin. Overall, [C-11]7 merits further evaluation in human subjects.
• PET MONITORING OF A-BETA-DIRECTED IMMUNOTHERAPY
  申请人：Black Ronald

  公开号：US20130084245A1

  公开（公告）日：2013-04-04

  The present invention provides methods of monitoring Aβ-directed immunotherapy. The methods involve administering a PET ligand that binds to amyloid deposits and detecting the PET ligand in the brain to provide an indication of the level and/or distribution of amyloid deposits. Surprisingly, the data in the present application show that a statistically significant reduction in amyloid deposits occurs early and consistently among patients following initiation of treatment before statistically significant effects of most if not all other markers are detectable. In consequence, the present methods allow early detection of whether a patient is responding to the Aβ-directed immunotherapy and if necessary adjustment of the immunotherapy regime.